Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans

Posted on by Research

John H. Halperna,,Correspondence information about the author John H. HalpernEmail the author John H. Halpern, Andrea R. Sherwoodc, James I. Hudsona, Deborah Yurgelun-Toddb, Harrison G. Pope Jra

Halpern, John H. et al.Biological Psychiatry, Volume 58, Issue 8, 624 – 631

Background

Hallucinogens are widely used, both by drug abusers and by peoples of traditional cultures who ingest these substances for religious or healing purposes. However, the long-term residual psychological and cognitive effects of hallucinogens remain poorly understood.

Methods

We recruited three groups of Navajo Native Americans, age 18–45: 1) 61 Native American Church members who regularly ingested peyote, a hallucinogen-containing cactus; 2) 36 individuals with past alcohol dependence, but currently sober at least 2 months; and 3) 79 individuals reporting minimal use of peyote, alcohol, or other substances. We administered a screening interview, the Rand Mental Health Inventory (RMHI), and ten standard neuropsychological tests of memory and attentional/executive functions.

Results

Compared to Navajos with minimal substance use, the peyote group showed no significant deficits on the RMHI or any neuropsychological measures, whereas the former alcoholic group showed significant deficits (p < .05) on every scale of the RMHI and on two neuropsychological measures. Within the peyote group, total lifetime peyote use was not significantly associated with neuropsychological performance.

Conclusions

We found no evidence of psychological or cognitive deficits among Native Americans using peyote regularly in a religious setting. It should be recognized, however, that these findings may not generalize to illicit hallucinogen users.

References

  1. IL; 1966
  2. Albaugh, B.J., Anderson, P.O. Peyote in the treatment of alcoholism among Native Americans. Am J Psychiatry. 1974;131:1247–1250
  3. American Indian Religious Freedom Act Amendments of 1994 (1994): 108 Statute 3124 Public Law 103-344. 42 USC.
  4. American Psychiatric Association. in: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Press, Washington, DC; 1994
  5. Bergman, R.L. Navajo peyote use (Its apparent safety) . Am J Psychiatry. 1971;128:695–699
  6. Blum, K., Futterman, S.L., Pascarosa, P. Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies (Possible biochemical rationale) . Clin Toxicol. 1977;11:459–472
  7. Burke, H.R. Raven’s Progressive Matrices (More on norms, reliability, and validity) . J Clin Psychol. 1985;41:231–235
  8. Calabrese, J.D. Spiritual healing and human development in the Native American Church (Toward a cultural psychiatry of peyote) . Psychoanal Rev. 1997;84:237–255
  9. Davies, A.R., Sherbourne, C.D., Peterson, J.R., Ware, J.E. Scoring Manual. RAND Corporation, Santa Monica, CA; 1988
  10. de Rios, M.D., Grob, C.S., Baker, J.R. Hallucinogens and redemption. J Psychoactive Drugs. 2002;34:239–248
  11. Garrity, J.F. Jesus, peyote, and the holy people (Alcohol abuse and the ethos of power in Navajo healing) . Med Anthropol Q. 2000;14:521–542
  12. Glick, S.D., Maisonneuve, I.M. Development of novel medications for drug addiction. The legacy of an African shrub. Ann N Y Acad Sci. 2000;909:88–103
  13. Grant, I. Alcohol and the brain (Neuropsychological correlates) . J Consult Clin Psychol. 1987;55:310–324
  14. Grinspoon, L., Bakalar, J.B. Psychedelic Drugs Reconsidered. The Lindesmith Center, New York; 1997
  15. Grob, C.S. Psychiatric research with hallucinogens (What have we learned?) . Yearbook for Ethnomedicine and the Study of Consciousness. 1994;3:91–112
  16. Halpern, J.H. The use of hallucinogens in the treatment of addiction. Addict Res. 1996;4:177–189
  17. Halpern, J.H., Pope, H.G. Do hallucinogens cause residual neuropsychological toxicity?. Drug Alcohol Depend. 1999;53:247–256
  18. Halpern, J.H., Pope, H.G. Hallucinogen persisting perception disorder (What do we know after 50 years?) . Drug Alcohol Depend. 2003;69:109–119
  19. Halpern, J.H., Pope, H.G., Sherwood, A.R., Barry, S., Hudson, J.I., Yurgelun-Todd, D. Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend. 2004;75:135–147
  20. Heaton, R. Wisconsin Card Sorting Test Manual. Psychological Assessment Resources, Odessa, FL; 1981
  21. Hollister, L.E., Sjoberg, B.M. Clinical syndromes and biochemical alterations following mescaline, lysergic acid diethylamide, psilocybin, and a combination of the three psychomimetic drugs. Compr Psychiatry. 1964;20:170–178
  22. Jastak Associates. Wide Range Achievement Test, Revision 3. ; 1993 (Division of Wide Range, 15 Ashley Place, Suite 1A, Wilmington, DE 19804-1314.)
  23. Johnston, L.D., O’Malley, P.M., Bachman, J.G. Monitoring the Future national results on adolescent drug use. National Institute on Drug Abuse, Bethesda, MD; 2003
  24. La Barre, W. in: The Peyote Cult. 5th ed. University of Oklahoma Press, Tulsa; 1989
  25. Lamarine, R.J. Alcohol abuse among Native Americans. J Community Health. 1988;13:143–155
  26. MacLeod, C. Half a century of research on the Stroop effect (An integrative review) . Psychol Bull. 1991;109:163–203
  27. Mail, P.D., Johnson, S. Boozing, sniffing, and toking (An overview of the past, present, and future of substance use by American Indians) . Am Indian Alsk Native Ment Health Res. 1993;5:1–33
  28. Manson, S., Shore, J., Baron, A., Ackerson, L., Neligh, G. Alcohol abuse and dependence among American Indians. in: J.E. Helzer, G.J. Canino (Eds.) Alcoholism in North America, Europe, and Asia. Oxford University Press, New York; 1992:119–130
  29. Menninger, K. Discussion of Bergman RL (1971): Navajo peyote use: Its apparent safety. (Am J Psychiatry 128:695-699)Am J Psychiatry. 1971;128:699
  30. Nichols, D.E. Hallucinogens. Pharmacol Ther. 2004;101:131–181
  31. Nichols, D.E., Pfister, W.R., Yim, G.K.W., Cosgrove, R.J. A new view of the structural relationship between LSD and mescaline. Brain Res Bull. 1977;2:169–171
  32. Osterrieth, P. Le test de copie d’une figure complexe. Archives de Psychologie. 1944;30:206–356
  33. Parrott, A.C. Human psychopharmacology of Ecstasy (MDMA) (A review of 15 years of empirical research) . Hum Psychopharmacol. 2001;16:557–577
  34. Pope, H.G. Cannabis, cognition, and residual confounding. JAMA. 2002;287:1172–1174
  35. Pope, H.G., Gruber, A.J., Hudson, J.I., Huestis, M.A., Yurgelun-Todd, D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58:909–915
  36. Pope, H.G., Gruber, A.J., Yurgelun-Todd, D. Residual neuropsychological effects of cannabis. Curr Psychiatry Rep. 2001;3:507–512
  37. Reitan, R., Wolfson, D. The Halstead-Reitan Neuropsychological Test Battery (Theory and Clinical Interpretation) . 2nd ed. Neuropsychology Press, Tuson, AZ; 1993
  38. Roy, C. Indian peyotists and alcohol. (letter to the editor)Am J Psychiatry. 1973;130:329–330
  39. Shulgin, A.T., Sargent, T., Naranjo, C. Structure–activity relationships of one-ring psychotomimetics. Nature. 1969;221:537–541
  40. Slotkin, J.S. in: The Peyote Religion. 1st ed. The Free Press, Glencoe, IL; 1956
  41. Snyder, S.H., Merril, C.R. A quantum-chemical correlate of hallucinogenesis. in: H.E. Himwich, S.S. Kety, J.R. Smythies (Eds.) Amines and Schizophrenia. Pergamon Press, Oxford; 1967:229–245
  42. Stewart, O. Peyote Religion (A History) . 1st ed. University of Oklahoma Press, Tulsa; 1987
  43. Stroop, J. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643–662
  44. Veit, C.T., Ware, J.E. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol. 1983;51:730–742
  45. Wechsler, D. A standardized memory scale for clinical use. J Clin Psychol. 1945;19:87–95
  46. Wechsler, D. Wechsler Adult Intelligence Scale-Revised Manual. Psychological Corp, Cleveland, OH; 1981

Leave a Reply

Your email address will not be published. Required fields are marked *